-
GLP-1RA Biweekly Formulation Outperforms Semaglutide!
GanLee
Ganlee Pharmaceuticals’ Phase II trials show promising results for innovative diabetes treatments. Their biweekly GLP-1RA, GZR18, demonstrates superior HbA1c and weight reduction compared to Semaglutide, while GZR4 and GZR101 also show favorable outcomes versus Insulin Degludec and Degludec/Aspart.
安西县|
时尚|
三台县|
郓城县|
修水县|
泊头市|
高雄市|
宜城市|
邢台县|
会泽县|
灵丘县|
隆昌县|
阿鲁科尔沁旗|
武宁县|
喀喇|
广昌县|
万山特区|
巢湖市|
泾阳县|
彭泽县|
千阳县|
金山区|
田林县|
云龙县|
安图县|
高要市|
泸定县|
元朗区|
德化县|
枝江市|
临夏市|
浮山县|
垦利县|
防城港市|
台南县|
沙河市|
宿州市|
苍南县|
陕西省|
于都县|
五莲县|
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
